Short answer
TG THERAPEUTICS, INC. (TGTX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Results cover the three and six months ended June 30, 2026.
TG THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Results cover the three and six months ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the operational and financial results
- Market relevance depends on the reported performance details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $240.3M, up from $141.1M; BRIUMVI U.S. sales $227.7M, up approximately 64% year over year
- 2026 guidance raised to approximately $950M global revenue and $890–905M BRIUMVI U.S. revenue
- Net income fell to $7.8M from $28.2M as R&D reached $95.3M and SG&A $82.1M
- Cash, equivalents and investments $612.3M, supporting commercialization and pipeline investment
- Positive ENHANCE results support single 600 mg initiation infusion; subcutaneous Phase 3 data expected year-end 2026 or early 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TG THERAPEUTICS, INC. 8-K filings
Get the next TGTX 8-K as it lands
Follow TGTX for push alerts, or ask the research agent what this filing means.